UTI — Universal Technical Institute, Inc. · 2026-09-10 · Verdict: PASS · Conviction 3
Price $21.29 (screen close 2026-09-09) · Mkt cap $1.17B · EV $1.16B · EV/normalised after-tax profit 33.2x · FCF yield negative · Net cash $10.1M · ADV $38.5M Sources read: 10-K 2025-11-26 (Items 1, 1A, 7), 10-Q 2026-08-06 (Item 2), DEF 14A 2026-01-20, 8-Ks 2026-05-06 and 2026-08-05 (Item 2.02) and 2026-08-18 (Item 1.01), Form 4s (trailing 12m), Q3 2026 earnings call transcript.
Desk stats - Revenue trend: FY2025 revenue $835.6M, up 14.0% on 10.5% growth in average full-time active students plus tuition increases (10-K 2025, Item 7). Q3 2026 revenue $218.9M, up 7.2%, on 5.8% student growth (Q3 release). Volume and price, not acquisition; the last deal was Concorde in December 2022. - Normalised after-tax operating profit: trailing twelve months to 30 June 2026, GAAP income from operations is $44.3M ($83.5M FY2025, less $58.5M for 9M FY2025, plus $19.3M for 9M FY2026). No impairments, no discontinued operations. Two add-backs from the Q3 reconciliation: restructuring $1.1M (phase I approved May 2026) and integration costs $1.4M. Normalised operating profit $46.7M against $44.3M GAAP; taxed at 25%, $35.0M. The ~$35M of "strategic growth expenses" management excludes is deliberately not added back, for the reason in section 3. - EV / normalised after-tax profit: 55.095M shares at $21.29 is $1,173.0M; add $160.0M debt ($157.0M long term, $3.0M current), subtract $130.1M cash and $40.1M short-term investments (10-Q balance sheet). EV $1,162.9M, so 33.2x. The FY2026 guidance midpoint of ~$86.2M EBITDA less ~$39.5M D&A gives the same 33x (Q3 release, guidance reconciliation). - Leverage: net cash $10.1M, so net debt / normalised EBITDA of $81.1M is roughly zero. That flatters a leased-campus operator: including the $199.4M of operating lease liabilities, adjusted net debt is $189.3M, or 2.3x. The $95.0M revolver draw was repaid in July with cash on hand (10-Q, Liquidity); August's refinancing lifted the revolver to $200M to 2031 (8-K 2026-08-18). - Is the growth sustainable? Organic and real in students, but not cash-backed: trailing operating cash flow $74.5M against $101.9M capex is free cash flow of negative $27.4M, and FY2026 adjusted free cash flow was cut to $(20)M to $0M on ~$110M capex (Q3 release). Guidance was cut, not raised. - What the screen got wrong: everything material. It ran on FY2025, which ended 30 September 2025, so it saw $83.5M of operating profit, 14.0% growth, $42.0M capex and a 4.7% FCF yield. On the last twelve months operating profit is $44.3M, capex $101.9M and free cash flow negative. The 19.2x screen multiple is 33.2x today. It also missed $40.1M of short-term investments and the $199.4M of leases.
1. What the business actually does
Two divisions (10-K 2025, Item 1). UTI runs 15 campuses in auto, diesel, welding, HVACR, electrical and aviation. Concorde, bought December 2022, runs 17 campuses plus online in allied health, dental and nursing. About 78% of revenue on a cash basis comes from Title IV and veterans' benefits, with institution-level 90/10 ratios of 67% to 82%. UTI also lends to its own students through a proprietary loan program and bears all the credit risk (10-K 2025, Item 7).
2. Why it is mispriced — the edge case
There is no edge case, and that is the finding. The stock is 58% below its 52-week high and the screen shows a cheap multiple only because it is reading a fiscal year that no longer describes the company. Nor is the seller indifferent. Coliseum Capital, whose principals Christopher Shackelton and Adam Gray sit on the board, held 3,971,440 shares, 7.2%, at the January record date (DEF 14A 2026). On 8 June 2026 the Coliseum entities sold 3,000,000 shares at $41.40 (Form 4, 2026-06-10); the CEO sold 94,500 at about $41.40 on 29 June (Form 4, 2026-06-30); three other officers and a director also sold. Trailing twelve month insider selling is $129.9M against $295K of buying, all by one director in four small purchases between $21.77 and $28.21 (form4_summary). The informed sellers left at roughly twice today's price, two months before the guidance cut.
3. Unit economics and growth
Operating margin was 10.0% in FY2025 and 8.0% in FY2024 (10-K 2025, Item 7); it is 2.9% for the nine months to June 2026 and 1.5% in Q3. Management attributes the collapse to ~$35M of strategic growth expenses and quotes baseline adjusted EBITDA above $135M against reported $100M to $103M (Q3 release). That add-back does not survive as a normalisation: management plans two to five new campuses and 12 to 20 program replications every year through fiscal 2029 and "$100 million or more" of annual capex (Q3 call). A cost budgeted for four consecutive years is an operating cost, and adding it back while still charging D&A on the assets it creates double counts.
The shortfall is also not only investment. The CFO bridged it: original guidance was adjusted EBITDA "north of $155 million," baseline is now about $135M, and "about 70%" of that ~$20M delta "is directly related to the auto diesel high school starts miss," 30% mix (Q3 call). The miss was self-inflicted: the company ran about 140 field representatives all year against a plan needing more, "did not get to all of the students that were inquiring," and has since hired to just over 170 (Q3 call, CEO). The mix piece is structural, since skilled trades programs run about nine months against 51 weeks to a year for auto and diesel, so each start carries less revenue (Q3 call, CFO). Underneath, the provision for credit losses was $22.4M in the nine months against $15.1M, up 49% on 7.8% revenue growth, after a $13.6M increase in FY2025; notes receivable are $52.1M and rising on "higher utilization of UTI's proprietary loan program" (10-Q). Company-funded student credit is growing faster than the students.
4. Balance sheet and capital allocation
The balance sheet is not the problem: net cash $10.1M, a new $200M revolver to August 2031 at SOFR plus 1.50% to 2.25%, covenants in compliance at 30 June (8-K 2026-08-18; 10-Q). Capital allocation is. No dividend and no buyback: the nine-month cash flow statement shows zero repurchases while $8.7M went out in payroll taxes on vesting stock. Stock compensation rose to $9.4M from $6.4M, guided to ~$12.3M, and shares outstanding rose 1.2% to 55.1M. Holders were diluted while the stock fell 58% and every executive with size sold.
5. Management: what they said vs what they did
On 6 May 2026, with six-month operating income already down 63.8%, the CEO was "reaffirming our full-year guidance across all metrics" citing "the visibility we have into the remainder of fiscal 2026" (Q2 release). Ninety days later revenue guidance fell to $893M-$900M from $905M-$915M, adjusted EBITDA to $100M-$103M from $114M-$119M, EPS to $0.57-$0.64 from $0.71-$0.80, and adjusted free cash flow to $(20)M-$0M from $20M-$25M (Q3 release). The staffing deficit causing most of the miss had, on the CEO's own account, run "throughout the year." That is a visibility failure on the exact quarter management had said all year would carry the year. The FY2029 target of $1.2B revenue and ~$220M adjusted EBITDA was reaffirmed unchanged.
6. Valuation
Bear (30%): the growth spend never converts, FY2029 adjusted EBITDA $140M, net debt $200M funding the burn, 6.5x. About $12.5 in 2029, $9.4 discounted three years at 10%. Base (45%): revenue compounds ~7%, FY2029 adjusted EBITDA $180M rather than $220M, net debt $120M, 8.0x. About $23.4 in 2029, $17.6 today. Bull (25%): the plan lands, $220M in FY2029, net debt $80M, 9.5x. About $35.3 in 2029, $26.5 today. Probability-weighted value is $17.4 against $21.29, about 18% below the price. Reverse DCF: at $21.29 the price implies management delivers the full FY2029 plan of $1.2B revenue and $220M adjusted EBITDA and that the market then pays about 15x normalised after-tax operating profit for it.
7. Catalysts and timeline
FY2027 guidance with the Q4 report in November 2026 is the one that matters; the CFO has pre-committed to "modest EBITDA growth" in 2027 off the reduced base. Q1 2027 starts will show whether the 20% larger field force converts the unworked lead backlog. The AHEAD negotiated rulemaking on the OBBBA "Do No Harm" earnings provisions, Gainful Employment and Workforce Pell runs alongside (10-K 2025, Item 1).
8. Risks and pre-registered kill criteria
- FY2027 guidance in November comes in with reported adjusted EBITDA above $125M and capex below $90M.
- Adjusted free cash flow turns positive for two consecutive quarters.
- Provision for credit losses falls below 2.5% of revenue for two consecutive quarters, from 3.4% in the nine months to June 2026.
- Insider net open-market buying exceeds $2M, or Coliseum re-buys, against $129.9M of net selling. Other risks: any institution breaching the 90/10 rule, where the range is already 67% to 82%; an adverse Gainful Employment or "Do No Harm" determination; MIAT and Concorde still operate under provisional program participation agreements (10-K 2025, Item 1).
9. Verdict and one-paragraph summary
PASS, conviction 3. UTI passed the screen on a fiscal year that ended almost a year ago, and on current numbers it is not cheap: trailing twelve month operating profit is $44.3M against $83.5M in FY2025, so the $1.16B enterprise value is 33x normalised after-tax operating profit, and free cash flow is negative $27.4M with FY2026 guided negative on ~$110M of capex. Student demand is genuine, with starts up 10.9% and the new San Antonio and Atlanta campuses running 30% to 40% ahead of their launch models, but management's invitation to look through $35M of strategic growth expenses to a $135M baseline is an add-back budgeted to recur in every year of a four-year plan, and the CFO conceded that about 70% of the $20M baseline shortfall came from a self-inflicted high school recruiting miss rather than from investment. The deciding facts are that guidance was reaffirmed in May and cut in August, and that Coliseum Capital, whose principals sit on the board, sold 3,000,000 shares at $41.40 in June alongside the CEO, against $295K of buying by one director. Probability-weighted value is about $17.4 against $21.29. There is no margin of safety here, only a stale screen row.
Research for discussion, not investment advice. Positions and sizing are the reader's decision.